Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Nerac IPDex™
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Webcasts / Webinar: Order 650 – China’s New CLE Requirements for Medical Devices

Webinar: Order 650 – China’s New CLE Requirements for Medical Devices

Facebook0
Google+0
LinkedIn0
Twitter0

Gain a working knowledge of the clinical literature evaluation process for China in the Nerac webinar hosted by FX Conferences: Order 650 – China’s New CLE Requirements for Medical Devices

Click here to register.

In 2014 the Chinese FDA updated its regulations for medical devices, Order 650, under which manufacturers are now required to perform and submit a formal review of the clinical literature. These updates have dramatically increased expectations for successfully applying for and ultimately obtaining approval to market and sell a medical device in China.

This presentation provides attendees with an overview of the clinical literature evaluation process, helps them understand the requirements, and provides tips on things to consider when conducting the evaluation of the clinical literature. Our speaker discusses the selection of predicate devices, creating the search protocols, what goes into the analysis of clinical literature, and sections of the final report.

Key learning points for attendees:

  • How to create a clinical literature evaluation to comply with Order 650 and the CFDA
  • Choosing a predicate device
  • Components of the predicate device table
  • Understanding the sections of Annex 6 and Annex 7 in the clinical literature evaluation process
  • How to choose and analyze appropriate clinical literature
  • The sections of the final report and the content that can be found there

Join Nerac Regulatory analyst Rich Conforti for this powerful discussion designed to give you the insights and information you need on the new CFDA regulatory proposals/guidances.

Be sure to register to attend!

Who should attend?
If you are a VP/Director of Regulatory or Clinical Affairs, VP/Director of R&D, VP/Director of Marketing, Product Manager or Quality Management System Representative, you don’t want to miss this webinar!

 

Related Posts

  • Understanding CFDA Expectations Regarding Clinical Literature Evaluation for Medical Devices under Order 650: A Nerac Perspective
    92
    By Richard Conforti, M.S., Nerac Analyst, Originally Published: April 19, 2016 In 2014 the Chinese Food and Drug Administration, CFDA, updated their regulations on medical devices. These updates substantially changed the way in which a medical device company, particularly international companies not based or founded in China, registers their devices in China. In part 1…
    Tags: devices, medical, cfda, china, clinical, literature, evaluation, order, process, device
  • Understanding CFDA Expectations Regarding Clinical Literature Evaluation for Medical Devices under Order 650: A Nerac Perspective Part III: The Final Clinical Literature Evaluation Report
    89
    By Richard Conforti, M.S., Nerac Analyst, Originally Published: August 15, 2016 In 2014 the Chinese Food and Drug Administration, CFDA, updated their regulations on medical devices. These updates substantially changed the way in which a medical device company, particularly international companies not based or founded in China, registers their devices in China. In the final…
    Tags: clinical, literature, devices, medical, cfda, evaluation, china, device, order, compliance
  • Understanding CFDA Expectations Regarding Clinical Literature Evaluation for Medical Devices under Order 650: A 3-Part Nerac Perspective
    81
    By Richard Conforti, M.S., Nerac Analyst, Originally Published: April-August, 2016 In 2014 the Chinese Food and Drug Administration, CFDA, updated their regulations on medical devices. These updates substantially changed the way in which a medical device company, particularly international companies not based or founded in China, registers their devices in China. In part 1 of…
    Tags: clinical, literature, devices, medical, cfda, order, evaluation, china, device, regulatory
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies energy EU MDR FDA food helga weires Industry 4.0 innovation Inspiring Next intellectual property IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation patenting patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting Tech Scouting XcellR8
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities
  • Privacy Policy

Copyright © 2023 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!

  • This field is for validation purposes and should be left unchanged.